In the future, as we build capacity and grow we will begin offering treatment as regulations allow, which will include:

  • MDMA-assisted psychotherapy for Posttraumatic Stress Disorder (PTSD), in collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS)
  • Psilocybin-assisted psychotherapy for end-of-life distress
  • Psilocybin-assisted psychotherapy for treatment-resistant depression

Our faculty will also begin collecting safety and quality improvement data to inform future clinical programming. An early priority will be to treat vulnerable populations who are historically underrepresented in clinical trials, including refugees, members from BIPOC and LGBTQ+ communities and individuals from low socioeconomic backgrounds. We will also recruit therapists from these communities to participate in its training program.

To make a donation to support Psychedelic Psychotherapy Research, please visit the UHN Foundation.

Back to Top